Skip to content

An observational study of immuneregulatory mechanisms in Juvenile Dermatomyositis

An observational study of immuneregulatory mechanisms in Juvenile Dermatomyositis - Immuneregulation in JDM

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57213
Enrollment
80
Registered
2011-04-12
Start date
2011-05-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

juvenile dermatomyositis

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Diagnosis juvenile dermatomyositis criteria van Bohan and Peter, ór referral to STC for non-inflammatory muscle weakness age

Exclusion criteria

Exclusion criteria: Age >18 jaar

Design outcomes

Primary

MeasureTime frame
The main objectives of the mechanism of disease part of study are: - establish the role of regulatory T cells (Treg cells) in muscle and in peripheral blood of JDM patients in active disease and in remission compared to children with non-inflammatory muscle neuromuscular disorders - responsiveness of Tregs to HSP60 and HSP70 - investigate the expression of HSP60 and HSP70 in muscle of JDM patients, compared to children with non-inflammatory neuromuscular disorders

Secondary

MeasureTime frame
- to investigate the homing of Treg cells to the site of inflammation (muscle) - to assess the local suppressive capacity of Treg cells in muscle tissue - to investigate the factors influencing the suppressive capacity of Treg cells - expression of cytokines in muscle of JDM patients - correlation between cytokine levels in serum and expression in muscle by multiplex assay - to correlate the cytokine levels to disease activity parameters (CMAS and myometrie, plus labresults) - compare these data to controls with other neuromuscular disorders than dermatomyositis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)